Scientists wanted to understand how efficient is Pfizer’s Paxlovid pill for COVID in the case of people of different age groups. Therefore, a study involving data from 109,000 patients has shown that while the risk of severe illness and death still goes down in the case of seniors who are at high-risk, it’s not the same when it comes to younger adults, meaning those between the ages of 40 and 65 years old. According to The Times of Israel, these latter fellows seem to show little to no benefit at all from the use of Pfizer’s pill for the coronavirus.
People after the age of 65 years old still don’t need to worry about the new study’s results. The research has shown that people in this age group were 75% less likely to need hospitalization after treatment with Paxlovid.
Dr. David Boulware, who’s a University of Minnesota researcher and also a physician, explained as The Times of Israel quotes:
Paxlovid will remain important for people at the highest risk of severe COVID-19, such as seniors and those with compromised immune systems,
But for the vast majority of Americans who are now eligible, this really doesn’t have a lot of benefit.
Back in March, we spoke about the ‘Test to Treat’ initiative of US President Joe Biden, which implied that a person would get free Paxlovid pills from the pharmacy if a coronavirus test returns a positive result.
Joe Biden stated as CNET quoted:
Thanks to the progress we have made this past year, COVID-19 need no longer control our lives. I know some are talking about ‘living with COVID-19.’ But tonight, I say that we will never just accept living with COVID-19.
The new research will probably make more people skeptical about the use of Paxlovid to treat COVID, although we’re expecting more news on the subject. The new work was published in the New England Journal of Medicine.
